Anticoagulants Market in the US 2016-2020

Overview of the anticoagulants market in the US

Technavio’s market research analyst predicts the anticoagulants market in the US to grow at a CAGR of more than 6% by 2020. Increase in the prevalence of deep vein thrombosis (DVT) and thrombosis along with the increased inclination shown toward surgeries which require anticoagulants administration is driving the growth of this market. Moreover, the rising number of the aged population has been adding to this market’s growth as they experience higher risks of developing cardiovascular and renal diseases, leading to thromboembolic and hemorrhagic conditions. With surging incidences of venous thromboembolism and valvular heart diseases among people over 60 years, the sales of anticoagulants in the US will accelerate over the next four years.

Several studies and investigations are being conducted to exploit the use of heparin as an anti-inflammatory and antitumor agent. Researchers are coming up with frequent innovations which have led to an increase in the development of heparin drugs as novel formulations and for the treatment of new indications. For instance, Ockham Biotech is developing inhaled heparin for the treatment of airway diseases, cystic fibrosis, and asthma either alone or in combination with other drugs under various stages of development.

Segmentation by route of administration (ROA) and analysis of the anticoagulants market in the US

• Oral
• Injectables

Oral anticoagulants occupied the largest segment of the market in 2015, in terms of ROA and accounted for more than 59% of the total market share. These drugs are used for several coagulation disorders, and primarily in the treatment of AF and DVT/PE. Factors such as approval of novel oral anticoagulants (NOACs), especially the class of factor Xa inhibitors and direct thrombin inhibitors, will augment the use of oral anticoagulants in the US.

Segmentation by drug class and analysis of the anticoagulants market in the US

• Heparin
• Factor Xa inhibitors
• Direct thrombin inhibitors
• Vitamin K antagonists

During 2015, the Factor Xa inhibitors accounted for the largest share of the market by holding around 42% of the total market. This segment comprises direct factor Xa inhibitors, which occupy 95% share of the market as all the NOACs are included in this class. The approval of NOACs such as rivaroxaban (Xarelto), edoxaban (Savaysa), and apixaban (Eliquis) will lead to the speedy growth of this segment in the coming years.

Competitive landscape and key vendors

The market is highly competitive with the presence of numerous small and large vendors. At present, the market is growing at a high pace because of the increased uptake of NOACs. Vendors are making investments in developing generic formulations for blood coagulation and other novel therapeutic areas. Recently, Daiichi Sankyo witnessed the approval of its oral anticoagulant, which has increased its market share considerably.

Key market vendors include -

• Boehringer Ingelheim
• BMS
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

Other prominent vendors in the anticoagulants market in the US are Armetheon, Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals, The Medicines Company, Urigen Pharmaceuticals, and Valeant Pharmaceuticals.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the anticoagulants market in the US?
• What are the key market trends impacting the growth of the anticoagulants market in the US?
• What are the challenges to market growth?
• Who are the key vendors in the anticoagulants market in the US?
• What are the market opportunities and threats faced by the vendors in the anticoagulants market in the US?
• Trending factors influencing the market shares of the US region.
• What are the key outcomes of the five forces analysis of the anticoagulants market in the US?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Heparin Market 2016-2020
• Global POC Diagnostics Market 2015-2019
• Global Clot Management Devices Market 2015-2019
• Global Hematology Analyzers and Reagents Market 2015-2019

Anticoagulants, also known as blood thinning agents, are drugs that prevent the formation of clots and helps in the free flow of blood in the body. Though they are referred to as blood thinning agents, they do not make the blood thinner, but instead interrupts the overall process of blood coagulation. In the US, vendors like BMS/Pfizer, Janssen Pharmaceutical, Janssen Pharmaceutical, Sanofi, and Aspen will be the primary players for anticoagulants.

The report, anticoagulants market in the US, is part of Technavio’s healthcare and life sciences research portfolio. This portfolio provides a comprehensive market analysis along with the market share, market sizing, and market segmentations covering areas such as cardiovascular and metabolic disorders, central nervous system, oncology, medical imaging, life science research tools, and vaccines. These market research reports provide a perspective on the various market opportunities and market threats along with the key trends that would influence the market growth during the forecast period. It presents insights into the changing competitive landscape and a detailed profiling and market analysis of the vendors. Also covered in the research are the key regions or countries that would have an impact on the market during the assessment years.